Coya Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Coya Therapeutics, Inc. | ||
| Date: March 18, 2025 | By: | /s/ Arun Swaminathan Ph.D. |
|---|---|---|
| Name: Arun Swaminathan Ph.D. | ||
| Title: Chief Executive Officer | ||
| Date: March 18, 2025 | By: | /s/ David Snyder |
| Name: David Snyder | ||
| Title: Chief Financial Officer (Principal Financial and Accounting Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Arun Swaminathan Ph.D. | Chief Executive Officer and Director | March 18, 2025 |
| Arun Swaminathan Ph.D. | (Principal Executive Officer) | |
| /s/ David Snyder | Chief Financial Officer | March 18, 2025 |
| David Snyder | (Principal Financial and Accounting Officer) Chief Operating Officer | |
| /s/ Howard Berman | Director and Executive Chairman | March 18, 2025 |
| Howard Berman | ||
| /s/ Ann Lee | Director | March 18, 2025 |
| Ann Lee | ||
| /s/ Anabella Villalobos | Director | March 18, 2025 |
| Anabella Villalobos | ||
| /s/ Dov Goldstein | Director | March 18, 2025 |
| Dov Goldstein | ||
| /s/ Wilbur Ross | Director | March 18, 2025 |
| Wilbur Ross | ||
| /s/ Dieter Weinand | Director | March 18, 2025 |
| Dieter Weinand | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| Statements of Operations for the Years ended December 31, 2024 and 2023 | F-4 |
| Statements of Stockholders’ Equity for the Years ended December 31, 2024 and 2023 | F-5 |
| Statements of Cash Flows for the Years ended December 31, 2024 and 2023 | F-6 |
| Notes to Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.